ZIM Laboratories announced key changes to its senior management structure on February 2, 2026, as the Board of Directors approved strategic appointments and categorizations recommended by the Nomination and Remuneration Committee. The pharmaceutical company disclosed these developments under Regulation 30 of SEBI (LODR) Regulations, 2015, with the event occurring at 08:24 p.m. on February 2, 2026.

Senior Management Appointments and Categorizations

The Board approved three significant changes to the company's senior management structure through a circular resolution:

New President - International Business

Vikrant Bendre joins ZIM Laboratories as President-International Business, bringing over 26 years of experience across strategic and operational roles. His extensive background includes:

• Previous role at JB Chemicals and Pharmaceuticals Limited, leading Branded Generics business for Rest of the World markets with full P&L responsibility
• Leadership experience across Southeast Asia, Middle East & Gulf region, Africa, and Latin America
• Significant exposure to regulated markets including United States, Canada, Australia, Japan, China, Brazil and Mexico
• Career progression through Panacea Biotec Limited, Jubilant Generics Limited, and Ipca Laboratories Limited

Bendre holds an MBA in Marketing from MIT School of Management, Pune, and a Bachelor's degree in Science from the University of Pune.

Human Resources Leadership

Jitendra Pandey, currently serving as Vice President-Human Resource, has been categorized as Senior Management Personnel. His responsibilities encompass:

• Overseeing Industrial Relations, Administration, and EHS functions
• Nearly two decades of diverse experience across multiple sectors and geographies
• Previous leadership roles at John Deere, Arvind Limited, and Alkem Laboratories
• MBA in Human Resources from Nagpur University

Quality Assurance Excellence

Sridhar Reddy, Vice President-Quality Assurance, has been elevated to Senior Management Personnel status. His expertise includes:

• Postgraduate in Pharmacy with over 29 years of experience in sterile and non-sterile pharmaceutical manufacturing
• Previous senior roles at Natco Pharma and Aurobindo Pharma
• Responsibility for overall site Quality functions and implementation of robust quality systems
• Primary Quality representative for regulatory inspections, customer audits, and external consultant visits

Reddy brings extensive experience in Quality Systems Management and has successfully led numerous regulatory inspections including US FDA, UK MHRA, EU authorities, ANVISA (Brazil), and audits from near-regulatory and emerging markets. He holds an M. Pharm. from BITS Pilani, India, and a B. Pharm. from Bangalore University.

Strategic Implications

These appointments strengthen ZIM Laboratories' leadership across critical business functions. The addition of Bendre as President-International Business signals the company's focus on expanding global operations, while the elevation of Pandey and Reddy to Senior Management Personnel status recognizes their strategic importance in human resources and quality assurance respectively.

ZIM Laboratories Limited has published newspaper advertisements announcing its Extraordinary General Meeting (EGM) scheduled for February 16, 2026, in compliance with regulatory requirements under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

EGM Details and Publication

The pharmaceutical company submitted newspaper publication copies to BSE Limited and National Stock Exchange of India Limited on January 22, 2026. The advertisements were published in three newspapers to ensure wide coverage across different linguistic communities.

Newspaper Coverage

The EGM notice was published in the following newspapers to comply with regulatory disclosure requirements:

• The Financial Express (English) - All India Edition
• Indian Express (English) - Nagpur Edition
• Lokatta (Marathi) - Local newspaper

This multi-language publication strategy ensures comprehensive reach to shareholders across different regions and language preferences.

Regulatory Compliance

The company's submission was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The notice was digitally signed by Piyush Siddheshwar Nikhade, Company Secretary and Compliance Officer (Membership No. A38972), demonstrating proper authorization and compliance protocols.

Meeting Accessibility

Shareholders will have multiple ways to access meeting information and participate in the proceedings. The EGM notice will be distributed through email to registered shareholders and made available on various digital platforms including the company's website and stock exchange portals.

The company has emphasized that the meeting will follow all applicable circulars issued by the Ministry of Corporate Affairs (MCA) and SEBI regarding virtual meetings and e-voting procedures. This approach aligns with current corporate governance practices that prioritize shareholder accessibility while maintaining regulatory compliance.